CA2028746A1 - Compositions pharmaceutiques et methodes de traitement des symptomes d'exces de table - Google Patents

Compositions pharmaceutiques et methodes de traitement des symptomes d'exces de table

Info

Publication number
CA2028746A1
CA2028746A1 CA2028746A CA2028746A CA2028746A1 CA 2028746 A1 CA2028746 A1 CA 2028746A1 CA 2028746 A CA2028746 A CA 2028746A CA 2028746 A CA2028746 A CA 2028746A CA 2028746 A1 CA2028746 A1 CA 2028746A1
Authority
CA
Canada
Prior art keywords
overindulgence
symptoms
treating
methods
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2028746A
Other languages
English (en)
Other versions
CA2028746C (fr
Inventor
William J. Goldman
Thomas N. Gates
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kenvue Brands LLC
Original Assignee
McNeil PPC Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23709269&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2028746(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by McNeil PPC Inc filed Critical McNeil PPC Inc
Publication of CA2028746A1 publication Critical patent/CA2028746A1/fr
Application granted granted Critical
Publication of CA2028746C publication Critical patent/CA2028746C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002028746A 1989-11-02 1990-10-31 Compositions pharmaceutiques et methodes de traitement des symptomes d'exces de table Expired - Lifetime CA2028746C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43083789A 1989-11-02 1989-11-02
US430,837 1989-11-02

Publications (2)

Publication Number Publication Date
CA2028746A1 true CA2028746A1 (fr) 1991-05-03
CA2028746C CA2028746C (fr) 1995-12-26

Family

ID=23709269

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002028746A Expired - Lifetime CA2028746C (fr) 1989-11-02 1990-10-31 Compositions pharmaceutiques et methodes de traitement des symptomes d'exces de table

Country Status (14)

Country Link
EP (1) EP0426479B1 (fr)
JP (1) JPH03206052A (fr)
KR (1) KR910009254A (fr)
AT (1) ATE101515T1 (fr)
AU (1) AU646230B2 (fr)
CA (1) CA2028746C (fr)
DE (1) DE69006684T2 (fr)
ES (1) ES2057439T3 (fr)
GR (1) GR1002097B (fr)
IE (1) IE64953B1 (fr)
IN (1) IN171746B (fr)
NZ (1) NZ235877A (fr)
PT (1) PT95753A (fr)
ZA (1) ZA908775B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69228738D1 (de) * 1991-12-06 1999-04-29 Glaxo Group Ltd Zusammensetzungen zur Behandlung von entzündlichen Zuständen oder Analgesie, die Ranitidin Wismuth Citrat und einen NSAID enthalten
CA2144155A1 (fr) * 1992-09-29 1994-04-14 Robert T. Sims Combinaisons d'antagoniste des recepteurs h2 et d'ibuprofene
GB9221414D0 (en) * 1992-10-13 1992-11-25 Glaxo Group Ltd Pharmaceutical compositions
US5648355A (en) * 1994-02-09 1997-07-15 Kos Pharmaceutical, Inc. Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
WO1998058637A1 (fr) * 1996-06-20 1998-12-30 Mcneil-Ppc Analgesique a base d'acetaminophene et de diphenhydramine
ZA975444B (en) * 1996-06-20 1998-12-21 Mcneil Ppc Inc Acetaminophen and meclizine hydrochloride analgesics
DE19801811B4 (de) * 1998-01-19 2004-12-23 Stada Arzneimittel Ag Pharmazeutische Zubereitung zur oralen Verabreichung
US7906153B2 (en) 1998-04-08 2011-03-15 Theta Biomedical Consulting & Development Co., Inc. Anti-inflammatory compositions for treating multiple sclerosis
US20050220909A1 (en) 2004-03-30 2005-10-06 Theoharides Theoharis C Composition for protection against superficial vasodilator flush syndrome
US7799766B2 (en) 1998-04-08 2010-09-21 Theta Biomedical Consulting & Development Co., Inc. Composition for treating hormonally-dependent cancers
GB9911017D0 (en) * 1999-05-13 1999-07-14 Zeneca Ltd Pharmaceutical compositions
IL145220A0 (en) * 1999-05-20 2002-06-30 Par Pharmaceutical Inc Stabilized composition based on pyridinyl-sulfinyl-benzimidazoles and process
WO2000074784A1 (fr) * 1999-06-09 2000-12-14 Eli Lilly And Company Combinaison pour le traitement du gain de poids lie a la prise de medicaments antipsychotiques comprenant un antipsychotique atypique et un antagoniste de type h2
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
EP1370261A2 (fr) * 2001-03-08 2003-12-17 AstraZeneca AB Utilisation nouvelle
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
EP2260837A1 (fr) 2001-06-01 2010-12-15 Pozen, Inc. Compositions pharmaceutiques pour l'administration coordonnée d'AINS
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20040185032A1 (en) * 2003-03-18 2004-09-23 David Burrell Compositions and methods for treating colic
US7923043B2 (en) 2004-03-30 2011-04-12 Theta Biomedical Consulting & Development Co., Inc. Method for protecting humans against superficial vasodilator flush syndrome
US7776873B2 (en) * 2005-12-01 2010-08-17 Yuhan Corporation Method for treating damage to gastric mucosa
PL2240018T3 (pl) * 2008-01-04 2017-01-31 Schabar Res Ass Llc Kompozycja zawierająca środek przeciwbólowy i przeciwhistaminowy
BRPI0918492A2 (pt) 2008-09-09 2015-12-01 Astrazeneca Ab uso de naproxen, ou sal farmaceuticamente aceitável do mesmo, e esomeprazol, ou sal farmaceuticamente aceitável do mesmo
EP2445499A4 (fr) 2009-06-25 2013-02-27 Astrazeneca Ab Procede pour le traitement d'un patient a risque de developer un ulcere associe a nsaid
US9176146B2 (en) 2009-08-03 2015-11-03 Theta Biomedical Consulting & Development Co., Inc. Methods of treating autism spectrum disorders and compositions for same
US9050275B2 (en) 2009-08-03 2015-06-09 Theta Biomedical Consulting & Development Co., Inc. Methods of screening for and treating autism spectrum disorders and compositions for same
UA115139C2 (uk) 2011-12-28 2017-09-25 Поузен Інк. Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
CA3124579C (fr) 2020-07-15 2026-03-31 Schabar Research Associates Llc Compositions de doses orales unitaires composees de naproxene sodique et de famotidine pour le traitement des douleurs aigues et la reduction de la gravite des aigreurs et/ou du risque d'aigreurs
US12514846B2 (en) 2020-07-15 2026-01-06 Schabar Research Associates Llc Unit oral dose compositions composed of ibuprofen or a pharmaceutically acceptable salt thereof and famotidine or a pharmaceutically acceptable salt thereof for the treatment of acute pain and the reduction of the severity and/or risk of heartburn and/or upset stomach
EP4181912A1 (fr) 2020-07-15 2023-05-24 Schabar Research Associates LLC Compositions de dose orale unitaire composées d'ibuprofène et de famotidine pour le traitement de la douleur aiguë et la réduction de la gravité et/ou du risque de brûlures d'estomac

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2105193B (en) * 1981-09-04 1984-09-12 Glaxo Group Ltd Pharmaceutical compositions containing non-steroidal anti-inflammatory agents
US4522826A (en) * 1984-02-08 1985-06-11 Richardson-Vicks Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
US4757060A (en) * 1986-03-04 1988-07-12 Bristol-Myers Company Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2, receptor blockers

Also Published As

Publication number Publication date
NZ235877A (en) 1992-09-25
DE69006684T2 (de) 1994-06-09
EP0426479A1 (fr) 1991-05-08
IE903946A1 (en) 1991-05-08
GR900100786A (el) 1992-04-17
AU6568990A (en) 1991-05-09
ZA908775B (en) 1992-07-29
EP0426479B1 (fr) 1994-02-16
ES2057439T3 (es) 1994-10-16
AU646230B2 (en) 1994-02-17
JPH03206052A (ja) 1991-09-09
IN171746B (fr) 1992-12-26
CA2028746C (fr) 1995-12-26
ATE101515T1 (de) 1994-03-15
GR1002097B (en) 1995-12-28
DE69006684D1 (de) 1994-03-24
IE64953B1 (en) 1995-09-20
PT95753A (pt) 1991-09-30
KR910009254A (ko) 1991-06-28

Similar Documents

Publication Publication Date Title
CA2028746A1 (fr) Compositions pharmaceutiques et methodes de traitement des symptomes d'exces de table
FI944712A7 (fi) Suun kautta annettavia opioidisia kestovaikutteisia formulaatioita
GEP20022812B (en) Using Cyclooxygenase-2 Inhibitors for Preparing Medicinal Means to Prevent Cardiovascular Disorders Connected with Inflammation Processes and Pharmaceutical Compositions Containing These Inhibitors
GEP20012388B (en) Metalloproteinase Inhibitors, Pharmaceutical Compositions on Their Base, Use and Methods for Obtaining and Intermediates
CA2214097A1 (fr) Emploi de ketorolac pour le traitement d'epithelioma spinocellulaires de la cavite buccale ou de l'arriere gorge
BE2013C026I2 (en) Use of an ingenane compound for the manufacture of a medicament for the treatment of cancer
CA2219115A1 (fr) Acides n-benzyl-3-indolacetiques en tant qu'inhibiteurs de la cycloozygenase-2 et medicaments anti-inflammatoires
CA2159450A1 (fr) 1-amidinophenyl-pyrrolidones piperidinones azetinones, inhibiteurs de l'agregation plaquettaire
CA2260213A1 (fr) Composes de pyridylpyrrole utiles comme antagonistes de l'interleukine et du facteur tnf
WO1992019617A3 (fr) Composes de dibenzoxazepine substituee, compositions pharmaceutiques et procedes d'utilisation
EP1167354A3 (fr) Huperzine A racémique
CA2140927A1 (fr) Inhibiteurs d'agregation plaquettaire
WO2005004915A3 (fr) Compositions contenant meloxicam
WO1996023771A3 (fr) Inhibiteurs de l'agregation plaquettaire
CA2116829A1 (fr) Utilisation d'un derive du pregnane
WO2001003688A3 (fr) Traitement de troubles induits par une cycloxygenase-2 au moyen de composes a base d'acides gras conjugues
TW325997B (en) Pharmaceutical composition for preventing and treating retinal diseases
CA2218643A1 (fr) Composition pharmaceutique orale de composes de piperidinoalcanol sous forme de solutions
CA2129676A1 (fr) Compositions antitussive de dextromethorphane
AU6970394A (en) Desoxyazaphospholipid derivatives having inhibiting activity on phospholipase a2
WO1999018930A3 (fr) Preparations pharmaceutiques
PL318539A1 (en) Inhibition of biosynthesis
WO2001039725A3 (fr) Preparations de medicaments
ES2058025A1 (es) Aplicacion del acido fitico y/o sus fitatos en los estados patologicos y prepatologicos derivados de la litiasis renal oxalocalcica idiopatica.
AU1305999A (en) (+)-ephedrine as a sympathomimetic drug

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry